Pattern of hospitalizations for angioedema in New York between 1990 and 2003.
BACKGROUND
The epidemiologic characteristics of angioedema have not been well described in the United States, especially regarding hospitalization patterns. This fact is particularly relevant given the increased use of angiotensin-converting enzyme inhibitors, a known cause of angioedema.


OBJECTIVE
To profile hospital admissions for angioedema in New York State with respect to age, sex, race, comorbidities, and year.


METHODS
A database of all acute hospitalizations in New York State was examined between 1990 and 2003. Patient admissions that had the principal admission diagnoses of angioedema and other acute allergic disorders (anaphylaxis, urticaria, or allergy unspecified) were extracted. Characteristics of angioedema admissions were tabulated and compared with those of other acute allergic disease admissions with respect to demographic variables and comorbidities.


RESULTS
There were 6,775 hospitalizations for angioedema during the study period. The number of angioedema hospitalizations increased progressively from 293 in 1990 to 636 in 2003, which exceeded the number of hospitalizations for anaphylaxis that year. African Americans constituted 42% of the angioedema admissions despite being less than 16% of the state population. The increase in hospitalizations for angioedema was most marked in patients with a diagnosis of hypertension, and for each study year, patients admitted with angioedema were consistently older than those admitted with other allergic disorders.


CONCLUSIONS
Angioedema has become the most common nonasthmatic acute allergic disorder that results in hospitalization in New York State. The predilection for angioedema occurring in patients with hypertension suggests that angiotensin-converting enzyme inhibitor use may play a role in this trend.
Lin
Robert Y
RY
New York Medical College, Valhalla, New York, USA. robert_lin@nymc.edu
Cannon
Ayana G
AG
Teitel
Ariel D
AD
D000293:Adolescent; D000328:Adult; D000707:Anaphylaxis / Q000453:epidemiology; D000799:Angioedema / Q000453:epidemiology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects; D044383:Black People; D015331:Cohort Studies; D005260:Female; D006760:Hospitalization / Q000639:trends*; D006801:Humans; D006967:Hypersensitivity / Q000453:epidemiology; D006973:Hypertension / Q000188:drug therapy; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009518:New York / Q000453:epidemiology; D012189:Retrospective Studies; D014581:Urticaria / Q000453:epidemiology; D044465:White People; D001741:Black or African American
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents